Evolution Research Group LLC, a privately held, independent clinical research site company in the United States, has promoted Andria Chastain to chief operating officer and the appointment of Paul Greene, PhD as chief business officer, it was reported yesterday.
Chastain has more than 20 years of experience in the clinical research industry and has been with the company since its inception. As COO, she will continue to manage clinical operations and recruitment activities across the company's portfolio of sites, working closely with site directors and principal investigators. She will also continue to be intimately involved with M&A strategy. She earlier served as senior vice president at the company.
Dr Greene joins the company after six years at Syneos Health and 25 years in the CRO and pharmaceutical industries. He has led product development teams and key customer relationships with a specific focus on central nervous system assets. A psychologist with post-doctoral training as an Eli Lilly Fellow, he has deep experience across the spectrum of CNS disorders with notable concentration in mood disorders, schizophrenia, and paediatrics. In his new role, he will lead corporate strategic growth initiatives and relationships, business development, client budgets and contracts, and marketing.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval